Bank of New York Mellon
MLYS icon

Bank of New York Mellon’s Mineralys Therapeutics MLYS Stock Holding History

Bank of New York Mellon’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Buy
158,550
+28,586
+22% +$784K ﹤0.01% 2534
2026
Q1 		$3.52M Sell
129,964
-1,875
-1% -$55K ﹤0.01% 2511
2025
Q4 		$4.78M Buy
131,839
+18,042
+16% +$724K ﹤0.01% 2348
2025
Q3 		$4.32M Buy
113,797
+17,382
+18% +$376K ﹤0.01% 2402
2025
Q2 		$1.3M Buy
96,415
+28,547
+42% +$414K ﹤0.01% 2972
2025
Q1 		$1.08M Buy
67,868
+2,550
+4% +$29.3K ﹤0.01% 3024
2024
Q4 		$804K Buy
65,318
+1,711
+3% +$22.4K ﹤0.01% 3280
2024
Q3 		$770K Sell
63,607
-21,155
-25% -$256K ﹤0.01% 3280
2024
Q2 		$992K Buy
84,762
+35,634
+73% +$449K ﹤0.01% 3206
2024
Q1 		$634K Buy
49,128
+2,196
+5% +$27.1K ﹤0.01% 3385
2023
Q4 		$404K Buy
46,932
+6,504
+16% +$51.1K ﹤0.01% 3671
2023
Q3 		$384K Buy
40,428
+217
+0.5% +$2.83K ﹤0.01% 3684
2023
Q2 		$686K Buy
40,211
+6,925
+21% +$104K ﹤0.01% 3426
2023
Q1 		$521K Buy
+33,286
New +$560K ﹤0.01% 3475

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

Bank of New York Mellon's MLYS Position: Q2 2026 in Review

Bank of New York Mellon increased its Mineralys Therapeutics (MLYS) stake by 22% in Q2 2026, buying an estimated $784K and bringing the position to 158,550 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2534.

Bank of New York Mellon first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $4.78M in Q4 2025. 60 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Bank of New York Mellon held 158,550 shares of Mineralys Therapeutics worth $4.28M as of Q2 2026.
  • Bank of New York Mellon bought 28,586 Mineralys Therapeutics shares in Q2 2026, an estimated $784K.
  • Mineralys Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2534 holding.
  • Bank of New York Mellon first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Bank of New York Mellon's Mineralys Therapeutics position peaked at $4.78M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.